Grant: CIHR Fellowship
McMaster University
$90,000.00
Developing AMPK activator as therapeutics for treatment and management of Inflammatory Bowel Disease
EF 2019-20
Résumé
Inflammatory bowel disease (IBD), that is commonly classified into Ulcerative colitis and Crohn's disease is the condition of inflammation in the gastrointestinal tract. The incidence of the disease has shown a dramatic increase in the last decades in Canada and worldwide. Despite significant progress in developing improved therapies for IBD, many side effects with existing therapies indicate the need for the development of better therapeutic strategies. The Adenosine monophosphate-activated protein kinase (AMPK) consist of catalytic alpha-subunit and the regulatory beta-and gamma-subunits and is a key regulator of cellular and organismal metabolism, however, the importance of AMPK in the pathogenesis of IBD is not fully understood. In our lab, we have investigated the important role of AMPK in the pathogenesis of intestinal inflammation. Our data suggest that reductions in AMPK activity mediated through genetic deletion of AMPK beta1 in macrophages up-regulates the production of pro-inflammatory cytokines and aggravates dextran sulfate sodium (DSS)-induced colitis in mice. We will further investigate the mechanism in the cellular level and investigate whether sodium salicylate, commonly used as anti-inflammatory and analgesic and recently an activator of AMPK targeting AMPK beta1, is effective in the amelioration of DSS-induced colitis in mice. The proposed study will prove to be very important in the development of safer and inexpensive therapy in the treatment and management of the condition of intestinal inflammation such as Inflammatory Bowel Disease which will benefit many Canadians and ultimately nations economy.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
412781
Name
Banskota Suhrid
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Developing AMPK activator as therapeutics for treatment and management of Inflammatory Bowel Disease
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Ampk Activator; Dss-Induced Colitis; Elisa; Inflammation; Inflammatory Cytokines; Myeloperoxidase Activity; Raw Macrophage; Western Blot
Abstract
Inflammatory bowel disease (IBD), that is commonly classified into Ulcerative colitis and Crohn's disease is the condition of inflammation in the gastrointestinal tract. The incidence of the disease has shown a dramatic increase in the last decades in Canada and worldwide. Despite significant progress in developing improved therapies for IBD, many side effects with existing therapies indicate the need for the development of better therapeutic strategies. The Adenosine monophosphate-activated protein kinase (AMPK) consist of catalytic alpha-subunit and the regulatory beta-and gamma-subunits and is a key regulator of cellular and organismal metabolism, however, the importance of AMPK in the pathogenesis of IBD is not fully understood. In our lab, we have investigated the important role of AMPK in the pathogenesis of intestinal inflammation. Our data suggest that reductions in AMPK activity mediated through genetic deletion of AMPK beta1 in macrophages up-regulates the production of pro-inflammatory cytokines and aggravates dextran sulfate sodium (DSS)-induced colitis in mice. We will further investigate the mechanism in the cellular level and investigate whether sodium salicylate, commonly used as anti-inflammatory and analgesic and recently an activator of AMPK targeting AMPK beta1, is effective in the amelioration of DSS-induced colitis in mice. The proposed study will prove to be very important in the development of safer and inexpensive therapy in the treatment and management of the condition of intestinal inflammation such as Inflammatory Bowel Disease which will benefit many Canadians and ultimately nations economy.
Competitiondate
201910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Banskota, Suhrid
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~